FGF21 and inherited lipid metabolism disorder: At the end of the 28-day treatment period, the usage of FGF21 analogue produced favourable effects on circulating lipid profiles (triglycerides, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol) and contributed to improvements in dyslipidaemia.